
Kym McNicholas interviews Sarvajna Dwivedi about his journey from developing asthma therapies to innovating in the field of peripheral artery disease.
What does it take to go from helping millions of people breathe easier to helping patients keep their legs? Join The Heart of Innovation as Kym McNicholas talks with Sarvajna Dwivedi, Ph.D., entrepreneur, inventor, and CEO of AngioSafe, whose career has spanned some of the most challenging problems in medicine. Sarvajna co-founded Pearl Therapeutics, a company focused on breakthrough respiratory therapies that was ultimately acquired by AstraZeneca for $1.15 billion. Along the way, he helped develop inhaled therapies and drug-device combinations designed to improve the lives of patients with asthma and COPD. (AngioSafe United States) Today, his focus has shifted from the lungs to the arteries. As CEO and co-founder of AngioSafe, Sarvajna is leading the development of the Santreva-ATK Endovascular Revascularization Catheter, a novel device designed to restore blood flow through some of the most challenging chronic total occlusions (CTOs) physicians encounter in patients with peripheral artery disease (PAD). The technology is designed to cross completely blocked arteries, compress plaque, create a new channel, and restore blood flow without relying on a guidewire or external power…
Host: Kym McNicholas
Guest: Sarvajna Dwivedi
Organizations: Pearl Therapeutics, AstraZeneca, AngioSafe, Medical Economics
Products: Santreva-ATK Endovascular Revascularization Catheter
Explore listener stats, chart rankings, contacts and more on the The Heart of Innovation with Kym McNicholas podcast page.